Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine

Electrothermal intradiscal annuloplasty therapies use radiofrequency energy sources to treat discogenic low back pain arising from annular tears. These annuloplasty techniques are designed to decrease pain arising from the annulus by thermocoagulating nerves in the disc and tightening of annular tissue.

Discogenic low back pain is a common, multifactorial pain syndrome that involves low back pain without radicular symptoms findings, in conjunction with radiologically confirmed degenerative disc disease. Typical treatment includes conservative therapy with physical therapy and medication management, with potential for surgical decompression in more severe cases.

A number of electrothermal intradiscal procedures have been introduced to treat discogenic low back pain; they rely on various probe designs to introduce radiofrequency (RF) energy into the disc. It has been proposed that heat-induced denaturation of collagen fibers in the annular lamellae may stabilize the disc and potentially seal annular fissures and that pain reduction may occur through the thermal coagulation of nociceptors in the outer annulus.

Some of the electrothermal intradiscal procedures are briefly described.

With the intradiscal electrothermal annuloplasty (IDEA) procedure, a navigable catheter with an embedded thermal resistive coil is inserted posterolaterally into the disc annulus or nucleus. Using indirect radiofrequency energy, electrothermal heat is generated within the thermal resistive coil at a temperature of 90 degrees centigrade; the disc material is heated for up to 20 minutes. Proposed advantages of indirect electrothermal delivery of radiofrequency energy with IDEA include precise temperature feedback and control, and the ability to provide electrothermocoagulation to a broader tissue segment than would be allowed with a direct radiofrequency needle.

Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) uses direct application of radiofrequency energy. With PIRFT, the radiofrequency probe is placed into the center of the disc, and the device is activated for only 90 seconds at a temperature of 70 degrees centigrade. The procedure is not designed to coagulate, burn, or ablate tissue. The Radionics RF Disc Catheter System has been specifically designed for this purpose.

Intradiscal biacuplasty involves the use of two cooled radiofrequency electrodes placed on the posterolateral sides of the intervertebral annulus fibrosus. It is believed that by cooling the probes a larger area may be treated than could occur with a regular needle probe.
Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine

Annuloplasty using a laser-assisted spinal endoscopy (LASE) kit to coagulate the disc granulation tissue (percutaneous endoscopic laser annuloplasty or PELA) has also been described.

Vertebral body endplates have been proposed as a source of lower back pain, caused by intraosseous nerves. The basivertebral nerve (BVN) enters the posterior vertebral body and sends branches to the superior and inferior endplates. Vertebrogenic pain, transmitted via the BVN, has been purported to occur with endplate damage or degeneration.

Regulatory Status
A variety of radiofrequency (RF) coagulation devices are cleared for marketing by the U.S. Food and Drug Administration (FDA), some of which are designed for disc nucleotomy. In 2002, the Oratec Nucleotomy Catheter (ORATEC Interventions, Menlo Park, CA, acquired by Smith & Nephew in 2002) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The predicate device was the SpineCATH® Intradiscal Catheter, which received FDA clearance for marketing in 1999. Radionics (a division of Tyco Healthcare group) RF (Radiofrequency) Disc Catheter System received marketing clearance through FDA’s 510(k) process in 2000.

The Baylis Pain Management Cooled Probe received marketing clearance through the FDA’s 510(k) process in 2005. It is intended for use “in conjunction with the Radio Frequency Generator to create radiofrequency lesions in nervous tissue.”

The Intracept Intraosseous Nerve Ablation System “is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care”. FDA reviewed the device and issued a substantially equivalent designation in August 2017 (K170827).

Note: This policy does not address disc nucleoplasty, a technique based on the bipolar RF device (Coblation®; ArthroCare, Austin, TX, acquired by Smith and Nephew, 2014). With the coblation system, a bipolar radiofrequency device is used to provide lower energy treatment to the intervertebral disc, which is designed to provide tissue removal with minimal thermal damage to collateral tissue. Disc nucleoplasty is closer in concept to a laser discectomy, in that tissue is removed or ablated in an effort to provide decompression of a bulging disc. Disc nucleoplasty and laser discectomy are considered separately in the policy entitled, Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty).

Related Policies:
Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty)
Automated Percutaneous and Endoscopic Discectomy

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine for the treatment of chronic back pain are considered investigational. BCBSNC does not provide coverage for investigational services or procedures.
Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine

**Benefits Application**
This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine are covered

| Not applicable |

When Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine are not covered

Intradiscal annuloplasty for the treatment of chronic discogenic back pain is considered investigational for all levels of the spine (i.e., cervical, thoracic, lumbar and sacral), whether performed percutaneously or using an open incision. This includes, but is not limited to, the following:

- Intradiscal electrothermal annuloplasty (IDEA)
- Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)
- Intradiscal biacuplasty

Intraosseous radiofrequency ablation of the basivertebral nerve (e.g., Intracept® system) for the treatment of vertebrogenic back pain is considered investigational.

**Policy Guidelines**

For individuals who have discogenic back pain who receive intradiscal thermal annuloplasty, the evidence includes a small number of randomized controlled trials (RCTs). Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Two RCTs on intradiscal electrothermal annuloplasty reported conflicting results, with one reporting benefit for intradiscal electrothermal annuloplasty and the other reporting no benefit. Further study in a sham-controlled trial with a representative population of patients is needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have discogenic back pain who receive intradiscal radiofrequency annuloplasty, the evidence includes two RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Neither RCT found evidence of benefit with the treatment. More sham-controlled trials are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have discogenic back pain who receive intradiscal biacuplasty, the evidence includes two industry-sponsored RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One trial reported significant improvements at 6 months posttreatment, but not at 1 and 3 months. The other trial also showed a significant reduction in visual analog scale (VAS) scores at 6 months that appeared to continue to the 12-month follow-up; however, it is unclear whether this trial was sufficiently powered. More sham-controlled trials are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.
Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine

For individuals who have vertebrogenic pain who receive ablation of basivertebral nerves, the evidence includes two RCTs (SMART and INTRACEPT trials). Relevant outcomes are symptoms, functional outcomes, quality of life and treatment-related morbidity. In one RCT, at 12 months, 73% of patients crossed over to the active treatment group and therefore long-term comparative data is not available. Limitations to the other RCT include lack of a sham control and short duration of follow-up. The evidence is insufficient to determine the effects of the technology on health outcomes.

Fischgrund and colleagues conducted a randomized, double-blind, sham controlled study (SMART trial) of basivertebral nerve (BVN) ablation using the Intracept system in 225 participants from the U.S. and Europe. (Fischgrund, 2018) Patients had chronic isolated lumbar pain that had not responded to at least 6 months of nonoperative management. Additional study inclusion criteria were a minimum Oswestry Disability Index (ODI) of 30 points (on a 100 point scale), a minimum VAS of 4 and Modic type 1 or 2 changes at the vertebral endplates of the levels targeted for treatment. Treatment was limited to a minimum of two and a maximum of three consecutive vertebral levels from L3-S1. The active treatment group (n=147) received radiofrequency and the sham group (n=78) underwent the same protocol for the same overall duration as the treatment group however the radiofrequency treatment was simulated. Patients were blinded to the group assignment for one year, at which time those in the sham arm were allowed to crossover, 57 (73%) of whom elected to do so, and receive the Intracept treatment. The primary endpoint of the original study was comparative change in ODI from baseline to 3 months, and in the intent to treat analysis there was no statistically significant difference in this outcome between groups at this time point. There was a difference between groups in the 3-month per protocol analysis (mean ODI improved 20.5 and 15.2 points in the treatment and sham arms, respectively; p=0.019). However, at the 12 month per protocol analysis, the difference in mean ODI between groups was no longer statistically significant. Pain severity, measured by VAS, was not significantly different between groups at 3 months (p=0.083) but there was significantly greater improvement in the treatment group at 6 and 12 months.

The 24 month follow-up results were reported for the active treatment group from the SMART trial. (Fischgrund 2019) Of the per protocol population treated with ablation (treatment arm), 106 (83%) completed a 24-month follow-up visit. A durable ODI mean improvement was observed (23.4 points). Data for ODI outcomes were not available for the sham group because of the high crossover rate. Therefore, long-term comparative outcomes are not available.

Five year results were reported for the 100 U.S. patients from the treatment arm from the original SMART trial who were available for follow-up. (Fischgrund 2020) Mean ODI scores improved from 42.8 to 16.9 at 5 years, a reduction of 25.9 points. Mean reduction in VAS score was 4.4 points (baseline 6.7, p<0.001).

The INTRACEPT trial was an open-label RCT conducted at 20 U.S. sites. (Khalil 2019) A total of 140 patients with lower back pain of at least 6 months duration, with Modic Type 1 or 2 vertebral endplate changes between L3 and S1 were randomized to undergo radiofrequency ablation of the BVN or continue standard care. Treatment of up to 4 vertebrae in non-consecutive levels from L3 to S1 was allowed. The primary study endpoint was change in ODI at 3 months. A pre-planned interim analysis was undertaken when 60% of participants reached the 3 month follow-up (n=51 in the treatment group and n=53 in the standard care group), and reported statistically significant differences between groups on all patient-reported outcome measures, favoring the treatment group. The study was halted and the individuals were allowed to cross over to the treatment arm. Study limitations include short term follow-up, lack of a sham group and allowance of crossover at 3 months.

Billing/Coding/Physician Documentation Information
Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 22526, 22527, 22899

Effective 1/1/2019: C9752, C9753

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources


Consultant review - 7/8/2001


BCBSA Medical Policy Reference Manual, 7.01.72, 7/12/02


Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine


Senior Medical Director – 8/2013


Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine


Medical Director review

Policy Implementation/Update Information

Intradiscal Electrothermal (IDET) Annuloplasty

7/6/09 Herniated Lumbar Disc. Percutaneous policy separated into individual policies by topic. No change to policy statement. Description revised. Updated rationale in the "Policy Guidelines" section. References added. (btw)

1/5/10 Deleted HCPCS codes 0062T and 0063T from the "Coding/Billing" section. (btw)

6/22/10 Policy Number(s) removed (amw)

Intradiscal Electrothermal (IDET) Annuloplasty and Percutaneous Intradiscal Radiofrequency Annuloplasty

6/21/11 Combined Intradiscal Electrothermal annuloplasty and Percutaneous Intradiscal Radiofrequency annuloplasty. Renamed “Intradiscal Electrothermal (IDET) Annuloplasty and Percutaneous Intradiscal Radiofrequency Annuloplasty”. Specialty Matched Consultant Advisory Panel review 5/25/2011. Updated “Description” and “Policy” statements to reflect these services. No change to policy intent. “Intradiscal annuloplasty (e.g., intradiscal electrothermal annuloplasty, percutaneous intradiscal radiofrequency thermocoagulation, or intradiscal biacuplasty) for the treatment of chronic discogenic back pain is considered investigational for all applications. BCBSNC does not provide coverage for investigational services or procedures.” References added. (btw)

8/30/11 Reference added. (btw)


8/21/12 Removed deleted CPT codes 0062T and 0063T from Billing/Coding section (btw)

9/18/12 Reference added. (btw)

7/1/13 Specialty Matched Consultant Advisory Panel review 5/15/2013. Policy Guidelines updated. No change to policy intent. (btw)
Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine

9/10/13  Policy Guidelines section updated. Removed HCPCS code S2348 from Coding/Billing section as it does not pertain to this policy. Senior Medical Director review 8/29/2013. Reference added. (btw)

6/10/14  Specialty Matched Consultant Advisory Panel review 5/27/2014. No change to policy. (btw)

11/11/14 Reference added. (sk)

7/1/15  Specialty Matched Consultant Advisory Panel review 5/26/2015. (sk)

9/1/15  Reference added. Codes 62292 and 64640 removed from Billing/Coding Section. (sk)

7/1/16  Specialty Matched Consultant Advisory Panel review 5/25/2016. (sk)

3/31/17  Reference added. Description section and Policy Guidelines Section revised. Title changed from Intradiscal Electrothermal (IDET) Annuloplasty and Percutaneous Intradiscal Radiofrequency Annuloplasty to Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, and Biacuplasty. Policy statement terminology revised to reflect the changes in the title but policy intent is unchanged. (sk)


3/9/18  Reference added. (sk)


12/14/18 Codes C9752 and C9753 added to Billing/Coding section for effective date 1/1/2019. (sk)


7/14/20  References added. Regulatory Status updated. Intraosseous radiofrequency ablation of the basivertebral nerve (e.g., Intracept® system) for the treatment of vertebrogenic back pain added to When Not Covered section. Policy Guidelines updated. Code 22899 added to Billing/Coding section. Title changed from Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, and Biacuplasty to “Percutaneous Intradiscal and Intraosseous Radiofrequency Procedures of the Spine”. Medical Director review. (sk)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.